South Korea PD-1 Antibody Drug Market was valued at USD 1.1 Billion in 2022 and is projected to reach USD 2.4 Billion by 2030, growing at a CAGR of 10.2% from 2024 to 2030.
The South Korea PD-1 Antibody Drug Market has emerged as a vital area of growth within the global pharmaceutical sector. PD-1, or Programmed Death-1, is a checkpoint inhibitor used primarily in cancer immunotherapy. As the demand for advanced cancer treatments increases, the market for PD-1 antibody drugs in South Korea has seen significant growth. These drugs have proven effective in treating various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. As a result, healthcare providers, researchers, and pharmaceutical companies are increasingly turning to PD-1 antibody drugs to address the growing need for innovative treatments.
South Korea’s healthcare industry, known for its technological advancements and cutting-edge medical research, plays a significant role in the PD-1 antibody drug market. The country’s strong pharmaceutical infrastructure and supportive government policies have created an environment conducive to the development and distribution of these drugs. Local biopharmaceutical companies are working on developing their own PD-1 inhibitors, while global companies like Merck and Bristol-Myers Squibb are also expanding their presence in the region.
Industries requiring PD-1 antibody drugs are broad, spanning healthcare, biotechnology, and pharmaceuticals. Hospitals and cancer treatment centers form the core of the demand for these drugs, as they are at the forefront of administering innovative cancer therapies. Pharmaceutical companies invest heavily in research and development to create next-generation PD-1 inhibitors that offer enhanced efficacy and fewer side effects. Additionally, South Korean biotech companies are exploring the potential of PD-1 antibodies in combination with other cancer treatments to improve patient outcomes.
Furthermore, regulatory approval and market access are key factors influencing the PD-1 antibody drug market in South Korea. The government’s support for clinical trials and drug approvals has accelerated the availability of PD-1 inhibitors in the country. As the population ages and the incidence of cancer increases, the need for these groundbreaking treatments is expected to continue growing.
With ongoing research, new drug formulations, and government backing, the South Korean PD-1 antibody drug market is poised to expand further, offering both challenges and opportunities for industry stakeholders.
Get an In-Depth Research Analysis of the South Korea PD-1 Antibody Drug Market Size And Forecast [2025-2032]
Â
Novartis
Thermo Fisher
InvivoGen
BioVision Inc.
Abcam
Bristol-Myers Squibb
Merck
Ono Pharmaceutical Co.
Ltd
Eli Lilly
Chugai Pharmaceutical Co.
Ltd
BeiGene
AbbVie
TG Therapeutics
Inc
Beijing Yiqiao Shenzhou Technology Co.
Ltd.
3SBio
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea PD-1 Antibody Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea PD-1 Antibody Drug Market
Monoclonal Antibodies
Bispecific Antibodies
Additional Formats (e.g., conjugated antibodies)
PD-1 Inhibitors
PD-L1 Inhibitors
Combination Therapies (PD-1 with other immunotherapeutics)
Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Urothelial Carcinoma
Others (e.g., Hodgkin Lymphoma, Renal Cell Carcinoma)
Intravenous (IV)
Subcutaneous (SC)
Oral
Hospitals
Specialty Clinics
Research Institutions
Home Healthcare Providers
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea PD-1 Antibody Drug Market Research Analysis
1. Introduction of the South Korea PD-1 Antibody Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea PD-1 Antibody Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea PD-1 Antibody Drug Market, By Type
6. South Korea PD-1 Antibody Drug Market, By Application
7. South Korea PD-1 Antibody Drug Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea PD-1 Antibody Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/